Reuters logo
Fresenius profit below poll on weak sales of blood substitute
May 6, 2014 / 5:45 AM / in 4 years

Fresenius profit below poll on weak sales of blood substitute

FRANKFURT, May 6 (Reuters) - German diversified healthcare group Fresenius SE posted slower earnings growth than expected, hurt by weak overseas currencies and a drop in sales of a blood volume substitute product.

Quarterly adjusted net income rose 2 percent to 228 million euros ($316 million), it said on Tuesday, lower than the consensus estimate of 244 million euros in a Reuters poll.

The group, which controls dialysis provider Fresenius Medical Care, said it still expected adjusted net income to increase by 2-5 percent, excluding the effect of currency swings.

Sales of a blood volume substitute called HES, which is given after blood loss, declined after regulators advised physicians to use it sparingly. ($1 = 0.7205 Euros) (Reporting by Ludwig Burger)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below